Navigation Links
InterMune Announces Closing of Public Offering of Common Stock
Date:9/26/2007

BRISBANE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it closed its public offering of 4,025,000 shares of common stock at a price to the public of $19.50 per share, including 525,000 shares of common stock, representing the exercise by the underwriters of their option to purchase additional shares in the offering. The net proceeds to the company of the offering are approximately $73.8 million, after payment of underwriting discounts and commissions, but excluding estimated offering expenses.

Goldman, Sachs & Co. acted as the sole book-running manager of the offering. Deutsche Bank Securities Inc. acted as co-lead manager and CIBC World Markets Corp. acted as co-manager of the offering.

These shares were issued pursuant to an effective shelf registration statement. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Printed copies of the final prospectus supplement and base prospectus relating to the offering may be obtained from Goldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Fax: 212-902-9316 or Email at prospectus-ny@ny.email.gs.com). A prospectus supplement relating to the offering has been filed with the SEC, and is available along with the base prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at http://www.sec.gov/.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2019)... ... November 08, 2019 , ... ... for use in pathology research, today announced the results of analyses examining ... enrolled in the phase 3 selonsertib studies (STELLAR). Strong correlations were demonstrated ...
(Date:11/5/2019)... POWAY, Calif. (PRWEB) , ... November 05, 2019 , ... Ole, a German Shepherd, was ... difficulty with stairs and jumping. Though his energy level and his willingness to play ... to veterinary surgeon Dr. Holly Mullen of VCA Emergency Animal Hospital and Referral Center ...
(Date:10/30/2019)... ... October 30, 2019 , ... Western University of ... innovation and technology play in educating the next generation of health care providers. ... and presentations by WesternU administrators and representatives of companies working with the University ...
(Date:10/22/2019)... ... October 22, 2019 , ... nQ Medical, Inc. of Cambridge, MA, was recognized ... List which was announced at a showcase event yesterday in Los Angeles. nQ competed ... business plans, and impressive near-term growth projections to be named one of the most ...
Breaking Biology Technology:
(Date:11/7/2019)... ... , ... R3 Stem Cell is now offering its comprehensive Online Stem ... to use during checkout is FIFTYOFF and applies to both the one month access ... therapies with over 12,000 successful stem cell procedures performed nationwide. A couple years ago, ...
(Date:11/5/2019)... ... 05, 2019 , ... Catalent, the leading global provider of ... consumer health products, today announced it will present at the upcoming World Orphan ... – 14, 2019. , On Wednesday, Nov. 13 at 3:20 p.m., Philip Wills, ...
(Date:10/30/2019)... ... October 29, 2019 , ... ... for SIEMENS ATELLICA® analyzers, Order Numbers 701sa & 704sa. The kits, in a ... UTP, and UUN. , Each VALIDATE® kit, liquid, ready-to-use, and prepared using the ...
Breaking Biology News(10 mins):